Screener
Relmada Therapeutics, Inc. RLMD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Net cash provided by financing activities | 156,574,345 | - |
| Net increase/(decrease) in cash and cash equivalents | 6,279,860 | (2,707,320) |
| Cash and cash equivalents at beginning of the period | 3,496,540 | 3,857,026 |
| Cash and cash equivalents at end of the period | $9,776,400 | $1,149,706 |
| Non-cash investing and financing activities: | ||
| Cashless exercise of warrants for common stock | (2,082) | - |
| Fees for issuance of common stock included in accounts payable | 2,400,000 | - |
| Fees for issuance of common stock included in accrued expenses | 3,858,011 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s cash & equivalents?
- Relmada Therapeutics, Inc. (RLMD) reported cash & equivalents of $9.78M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Relmada Therapeutics, Inc.'s cash & equivalents increased by 750.3% year-over-year, from $1.15M to $9.78M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s cash & equivalents has grown at a 7.0% compound annual growth rate (CAGR), from $2.5M to $3.5M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Relmada Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude